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Abstract  
Introduction: Acute urinary retention due to benign prostatic enlargement is one of the clinical complaints 
that patients refer to the emergency department. Selective α-blockers are used after urinary catheterization. 
Recently, the use of nitrate compounds has been shown to relieve bladder neck and to treat acute urinary 
retention.  
Objective: The aim of this study was to survey the addition of Isosorbide di nitrate to tamsulosin in the 
treatment of acute urinary retention in patients with benign prostatic hyperplasia.  
Methods: This is a randomized, double-blind placebo-controlled clinical trial. In all, 78 patients with benign 
prostatic hyperplasia-related acute urinary retention referred to the emergency department were divided into 
two groups and randomly assigned to receive either 0.4 mg tamsulosin plus placebo or 0.4 mg tamsulosin plus 
isosorbide dinitrate 40 mg extended-release tablets daily for 3 days. At the same first visit, the catheter was 
removed and the ability to void in same time and 1 month later was assessed in each group.  
Results: After catheter removal, 27 (67.5%) patients in the tamsulosin plus placebo group and 31 (81.6%) in 
the tamsulosin plus isosorbide dinitrate group voided successfully after 3 days (p = 0.155). After 1 month, 20 
(50.0%) patients taking tamsulosin plus placebo and 23 (60.5%) taking tamsulosin plus isosorbide dinitrate 
could void, yet indicating no significant difference (p = 0.350). 
Conclusions: Addition of isosorbide dinitrate to α-blockers has advantage in improving benign prostatic 
hyperplasia-related acute urinary retention versus tamsulosin alone, although was not statistically significant. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a benign 
prostatic neoplasm and its prevalence is associated 
with age, affects 75% of people over 70 years old 
(1). One of the complications in people with BPH is 
acute urinary retention (AUR) (2). Incidence of 
AUR is different in various societies and its rate is 
between 2.2 to 25 per 1000 person-years (3, 4). 
AUR is an unbearable and painful condition which 
is associated with pain requiring emergency 
urinary catheterization procedure (5, 6). On the 
other hand, there is potential morbidity in using 
long-term urinary catheterization leading to an 
increase in the tendency to trial without catheter 
(TWOC) (7). Using selective α-blockers (alfuzosin, 
tamsulosin, and silodosin) has resulted in the 
success of TWOC, a short period of time after 
catheterization (8, 9). It was reported that, 1-3 days 
after catheterization in AUR patients, the success 
rate of TWOC has risen from 23% to 77% (7, 10, 
11). It has been indicated that using nitrate 
compounds relaxes the bladder neck muscles and 
recovers AUR in patients with BPH (12-14). Some 
studies have also revealed that daily use of 
isosorbide dinitrate (ISDN) was not effective in 
recovering the retention symptoms of the lower 
urinary tract (15). This study aimed at 
investigating the effect of adding ISDN to 
conventional treatment with tamsulosin in AUR 
patients due to BPH in increasing the success rate 
of TWOC.  
Methods 
Study design and setting  
This study is double-blind clinical trial research 
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carried out from 2016 to 2018 in the emergency 
department (ED) of Imam Khomeini Teaching 
Hospital, the largest center with patient referral in 
Sari, the north of Iran. During a year, approximately 
70000 patients refer to the hospital and of whom, 
about 200 refer because of AUR.  The convenience 
sampling conducted this study and researcher in 
hospital shifts in study period (2016-2018), 
included all patients who met the study inclusion 
criteria.  It was approved by the Ethics Committee 
of Mazandaran University of Medical Sciences 
(code: IR.MAZUMS.IMAMHOSPITAL.REC.95.2440). 
The research started after registering in the Iranian 
Registry of Clinical Trials (www.irct.ir) under the 
code of IRCT2017041724606N3. Written consent 
was obtained from the patients or their next of kin.  
Study population 
All patients with BPH who suffered AUR and had 
referred to the ED entered the study. All had a 
feeling of urgent urination and complained of pain 
in the suprapubic area. Bladder distention in these 
patients was detected by using a portable 
ultrasound device in the ED. After urinary catheter 
insertion (Foley catheter), the symptoms 
disappeared. Those patients with history of renal 
failure, diabetes, active urinary tract infection, 
previous urinary tract surgery, urinary system 
malignancy and contraindications to the use of 
tamsulosin and ISDN as well as those with 
unsuccessful urinary catheterization and those 
who didn’t refer for reassessment were all 
excluded the study (Figure 1). 
Protocol  
Eligible patients underwent urinary 
catheterization. All the information about the age, 
previous history of urinary retention, underlying 
disorders, and medication were obtained from the 
patients and their urine voiding volumes were 
recorded. Then, renal function test requested, and 
also prostate volume measurement were done by 
ultrasound. Afterward, the patients were assigned 
into two groups; the first group (T) included 
patients who received daily tamsulosin 0.4 mg 
capsule (Modava Co) and placebo tablet (similar in 
size, color, and form to ISDN, made in 
Pharmacology Laboratory, Pharmacy School, 
Mazandaran University of Medical Sciences). The 
second group (I) were those who received 
tamsulosin 0.4 mg capsule (Modava Co.) and ISDN 
40 mg extended-release tablets (Aryan Co.) once 
daily. Computer-generated randomization was 
utilized to randomize the patients, that is, every 
other patient was assigned to one of the groups. 
The medication was prepared in the same number, 
form, and size and was packed and labeled by a 
number in opaque envelopes by the principal 
investigator. Then, the envelopes were given to the 
pharmaceutic nurse in the emergency department. 
Each patient was assigned a number by the 
emergency department pharmaceutic nurse based 
on the randomization table and consistent with 
that number, one of the opaque envelopes was 
given to the patients. The medication in the 
envelopes sufficed for 3 days and after that period, 
the patients were reexamined, their urinary 
catheters were removed, and TWOC was assessed. 
The patients were followed up weekly for one 
month and their need to use catheterization was 
scrutinized. All the information was recorded by 
the researcher, though none of the patients, 
pharmaceutical nurse, and researcher knew about 
the type of medication. The only person who was 
aware of the codes was the principal investigator 
who was not involved in the study process. 
Outcome 
The primary outcome was TWOC rate, and the 
secondary outcome included urine voiding volume, 
prostate volume, and catheterization need. The 
patients were asked about TWOC after 3 days. 
Urine voiding volume was measured using a urine 
bag with measured volume meter. A radiology 
faculty member measured the prostate volume 
using ultrasound. In a weekly follow up, the 
patients’ need to the second catheterization was 
recorded.  
Statistical Analysis  
The data were fed into SPSS version 17. The 
quantitative data were explained using measures 
of central tendency, like mean and median with 
standard deviation (SD) and interquartile range 
(IQR); the qualitative data were explicated using 
frequency and percentage. We used Chi-square test 
for comparing categorical variables and used 
Fisher's exact test for comparison with 20% of 
expected count have less than five or the minimum 
expected count was lower than one. The normality 
assumption of quantitative variable assessed with 
Shapiro-Wilk test and graphical approaches, like Q-
Q plot and histogram.  To compare the quantitative 
variables in the two groups, we used Independent 
t-test for normality distributed variable and Mann-
Whitney U test was employed in low sample size 
comparison and non-normality distributed. In all 
statistical test P-value less than 0.05 was 
considered as a statistically significant. 
RESULTS 
During the study period, about 178 patients with 
AUR had referred to the hospital and finally 
analyzed data of 40 and 38 patients in tamsulosin-
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placebo and tamsulosin-ISDN group, respectively 
(Figure 1).  
The patients aged from 55 to 92 in both group and 
mean age was not significant difference (p=0.624). 
The positive history of AUC and positive drug 
history was 20.0% and 40.0% in Tamsulosin-
placebo group, 18.4% and 28.9% in Tamsulosin-
ISDN group, respectively. The previous history of 
AUR, drug history, and also renal function, prostate 
volume and urinary retention volume were not 
statistically significant difference in two treatment 
group (p>0.05) (Table 1). All patients in both 
treatment groups had hypogastric pain, dilated 
bladder, and a strong feeling of urination. Also, in 
all patients, the size of the kidneys and bladder was 
normal.  
After 72 hours TWOC in patients with the 
tamsulosin-ISDN group, was higher than in the 
tamsulosin-placebo group (81.6% vs 67.5%), but 
this difference was not statistically significant 
(p=0.155). But over the course of a month, there 
was a greater need for urinary re-catheterization in 
the tamsulosin-placebo group (50.0% vs 39.5%), 
although, this difference was not statistically 
significant (p=0.350). The need for urinary re-
catheterization in one- and two-week follow-up 
 
Figure 1: Screening and Enrollment flow diagram 
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time in tamsulosin-placebo was higher than 
tamsulosin-ISDN group. Although, this difference 
was not statistically significant (p>0.05). Also, in 
each group one patients need for urinary re-
catheterization every three weeks (Figure 2).   
Patients who had TWOC after 72 hours were 
younger than those who did not have TWOC in both 
treatment group, but this difference was not 
statistically significant (p>0.05). In the tamsulosin-
isosorbide denitrite group, patients who had TWOC 
after 72 hours, prostate volume [Median (IQR): 30 
(20) vs 50 (10); p=0.005] and retention volume 
[Median (IQR): 200 (250) vs 450 (270); p=0.005] 
were significantly lower than failed TWOC. Also, 
this difference was obtained in tamsulosin-placebo 
group (Table 2). The successful TWOC was 
Table 1: Baseline characteristics of the patients 
Variable 
Tamsulosin – placebo 
(n= 40) 
Tamsulosin – Isosorbide dinitrate 
(n=38) 
P-value 
Age (year), mean ± SD 71.58 ± 9.95 70.5 ± 9.28 0.624 
Serum urea, mean ± SD 45.45 ± 7.66 46.32 ± 6.44 0.592 
Serum creatinine, mean ± SD 1.26 ± 0.18 1.28± 0.16 0.576 
Retention volume (cc), mean ± SD 287.38 ± 151.63 287.24 ± 145.14 0.997 
Prostate volume (cc), mean ± SD 38.45 ± 11.93 37.61 ± 13.50 0.845 
Positive history of AUC, n (%) 8 (20.0) 7 (18.4) 0.860 
Positive drug history, n (%) 16 (40.0) 11 (28.9) 0.305 
 
 
Table 2: The age, prostate volume and retention volume difference in successful and failed TWOC patients by treatment group 
Variable Tamsulosin + 
Successful TWOC Failed TWOC 
P value* 
Mean ± SD Median (IQR) Mean ± SD Median (IQR) 
Age (year) 
Placebo 70.44 ± 11.25 73 (59, 75) 73.92 ± 6.20 74 (69, 80) 0.317 
ISDN 69.23 ± 9.49 73 (60, 75) 76.14± 5.98 78 (73, 81) 0.076 
Prostate volume (cc) 
Placebo 36.22 ± 12.72 30 (25, 45) 43.08 ± 8.79 45 (40, 50) 0.089 
ISDN 34.48 ± 11.57 30 (25, 45) 51.43 ± 13.45 50 (40, 50) 0.005 
Retention volume (cc) 
Placebo 260.93 ± 150.55 200 (100, 400) 342.31 ± 144.11 400 (150, 450) 0.036 
ISDN 268.87 ± 142.15 200 (150, 400) 368.57 ± 139.33 450 (180, 450) 0.017 
ISDN: Isosorbide dinitrate; IQR: Interquartile Range (Q1, Q3); TWOC: Trial Without Catheter 
*. P-value based-on Mann–Whitney U test 
 
 
Figure 2: Need for urinary re-catheterization in follow-up time by treatment group 
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significantly higher in patients with urinary 
retention for the first time than in those with a 
history of acute urinary retention in tamsulosin-
ISDN (85% vs 15%, p=0.018) and also in 
tamsulosin-placebo group (100% vs 0%, p=0.001) 
(Figure 3).   
Discussion 
This clinical trial study revealed that adding ISDN 
to oral tamsulosin in comparison to tamsulosin per 
se for the treatment of patients with AUR has no 
effect on TWOC after 72 hours in the two groups. 
Moreover, one-month follow-up showed no 
significant differences between the two groups for 
re-catheterization. The growing success of TWOC 
by alpha antagonists such as tamsulosin has been 
approved in many studies (16, 17). However, the 
effect of using drug combination with tamsulosin 
such as 5α-reductase inhibitors, Finasteride, is not 
yet clear in AUR improvement (18). This study also 
showed that adding nitrate combination to 
tamsulosin brings about no change in the rate of 
TWOC among the patients and it was not successful 
in the treatment of AUR due to BPH. It has been 
found that some medications such as ISDN can 
improve urinary parameters like peak urinary flow 
rate and can be used for AUR (13, 14). Moreover, 
long-term use of such medications can reduce the 
proliferation of prostate tissue and prevent BPH 
progression (12). Similarly, using α-blockers 
results in the reduction of urine frequency and AUR 
relapse (19). Those who aged over 65 with a 
prostate volume of over 35cc had less TWOC level 
and increased odds of re-catheterization (20). 
Therefore, in this study age and prostate volume 
were considered as the effective factors in TWOC. 
Similar to other studies, this study has also 
confirmed that a history of lower urinary tract 
obstruction and excessive urine volume during 
initial catheterization are directly associated with 
failed TWOC (21, 22). Although several studies 
have revealed that retained urine volume has no 
significant relationship with the success rate of 
TWOC (21), this study found out that it was 
significantly higher in the failed TWOC group. 
Consequently, old age, high prostate volume, 
excessive urine volume, and history of lower 
urinary tract symptoms in a patient with AUR due 
to BPH are indicative of failed TWOC in 72 hours, 
so the patient should be referred to an urologist for 
surgery.  
Limitations 
First of all, the sample size and power of study were 
low, and although there was a difference in results, 
 
Figure 3: The prevalence of successful TWOC in negative and positive history of retention by treatment group 
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due to the low power and sample size, we probably 
did not find a significant statistical difference in the 
study. The other limitation was that most of the 
patients were old, so they didn’t refer for follow-up 
and they didn’t provide us with information about 
their previous illnesses and medication; this led to 
problems in sampling. Since this emergency 
department is the referral center for urology 
patients all over the province, most of the patients 
are referred after a failed treatment in other 
centers; this may cause an error in sampling, too. 
Finally, aerodynamic parameters were not 
measured in this study and patients’ follow-up and 
definitive treatment were not investigated. Hence, 
it is recommended that other studies apply nitrate 
drugs for a longer period and evaluate 
aerodynamic criteria in patients with AUR due to 
BPH.  
CONCLUSIONS 
Short-term use of ISDN along with tamsulosin in 
patients with BPH does not considerably affect 
TWOC in comparison to the use of tamsulosin per 
se. However, factors such as older age, previous 
history of AUR, increased prostate volume, and 
retention volume have contributed to the failure of 
TWOC. 
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